Category: Updates

Strictest patent laws will foster genuine innovation

In 2005, as the Indian Parliament debated at length the impact of complying with the WTO’s TRIPS Agreement, one issue was uppermost in their minds; the impact of granting patents on access to affordable generic medicines. And, the one medicine that exemplified the concern was imatinibmesylate, sold by Novartis as...

Read More

Glivec ruling: Putting patients before profits

Supreme Court’s verdict on Glivec benefits not just millions in India, but across the developing world Anand Grover Novartis’s assertions that the ruling will affect investment or future innovations have been belied time and again, including at the World Health Organization, which has found that intellectual property does not result...

Read More

Rally to oppose EU-India FTA, 10 April 2013

Date: 10 April 2013 Venue: Barakhamba road to Jantar Mantar, Delhi Time: 11:00 am to 12:30 pm Around 2000 people including people living with HIV (PLHIV), patient groups and public health activists will take to the streets and rally from Barakhamba road to Jantar Mantar at 11.00 am on 10...

Read More

Novartis case: Supreme Court’s historic decision on Section 3(d)

Anand Grover | Apr 2, 2013, 03.11 AM IST After 2005 India started granting product patents on medicines. However, Section 3(d), one of the safeguards introduced by Parliament, seeks to prevent patenting of new forms of known substances unless they exhibit enhanced efficacy. Were it not for section 3(d), the...

Read More
Page 10 of 13« First...89101112...Last »